Publications by authors named "Pina Brianti"

Purpose: Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildrakizumab 200 mg versus tildrakizumab 100 mg in patients with a high disease burden or high body weight.

Materials And Methods: Our retrospective study included 134 patients treated with tildrakizumab 200 mg and 364 patients treated with tildrakizumab 100 mg from 28 Italian Dermatology Units affected by moderate-to-severe plaque psoriasis.

View Article and Find Full Text PDF
Article Synopsis
  • Genital psoriasis affects about 60% of psoriasis patients, presenting challenges in treatment, but IL-17 inhibitors like bimekizumab have shown promise for this difficult condition.
  • A 16-week study on 65 participants revealed that 98.4% achieved clear improvement in genital psoriasis, demonstrating both effective symptom relief and enhanced quality of life.
  • The results indicate bimekizumab could be a beneficial treatment for genital psoriasis, but further research with larger and longer studies is needed to confirm these findings.
View Article and Find Full Text PDF
Article Synopsis
  • Bimekizumab, a monoclonal antibody targeting Interleukin-17 A and F, is effective for moderate-to-severe plaque psoriasis, though real-world data is limited.
  • A retrospective study in 19 Italian hospitals assessed 237 patients treated with bimekizumab, measuring psoriasis severity at 4 and 16 weeks based on PASI scores.
  • Results showed significant improvements in skin clearance and quality of life, with 75.4% achieving clear skin by week 16, and side effects were minimal and manageable.
View Article and Find Full Text PDF

Purpose: Secukinumab is a fully human monoclonal antibody that inhibits interleukin (IL)-17A approved for the treatment of moderate to severe plaque psoriasis in adults and children. We compared the efficacy and safety of secukinumab in patients aged < 65 years (adult patients) versus patients aged ≥ 65 years (elderly patients) in a post-hoc analysis of the SUPREME study.

Patients And Methods: Patients with moderate to severe plaque psoriasis received subcutaneous secukinumab 300 mg per week for the first 5 weeks, then 300 mg per month.

View Article and Find Full Text PDF

The treatment of early-stage penile carcinoma is usually represented by wide excision or partial penectomy with or without inguinal lymph node dissection. However, laser ablation of the tumor may have a prominent role as an organ-sparing approach. In this regard, the combination of UltraPulse CO laser and photodynamic therapy (PDT) may be a valid option, especially when surgery is not feasible or refused.

View Article and Find Full Text PDF
Article Synopsis
  • Atopic dermatitis (AD) and psoriasis (PsO) are commonly perceived as exclusive skin conditions, but this report reveals that they can coexist or develop sequentially in the same patient.
  • In a study of 12 patients, 8 with a history of PsO later developed AD, while 4 AD patients subsequently developed PsO, suggesting interconnected inflammatory pathways.
  • The report emphasizes the need for clinicians to monitor treatments and changes in skin conditions closely, as the underlying mechanisms for these overlapping diseases remain unclear.
View Article and Find Full Text PDF
Article Synopsis
  • Psoriasis is a chronic inflammatory skin disorder without approved clinical biomarkers for diagnosis and patient follow-up, but extracellular vesicles (EVs) are emerging as a potential tool for assessing the disease.
  • A study compared the phospholipid profiles of EVs from psoriatic patients undergoing treatment with systemic biological drugs to those from untreated patients and healthy donors, revealing significant differences in vesicle concentration and lipid composition.
  • Findings suggest that analyzing lipid alterations in circulating EVs could provide valuable insights for the diagnosis and treatment response in psoriasis patients.
View Article and Find Full Text PDF

: Vitiligo is an acquired chronic and idiopathic skin disorder, characterized by selective loss of melanocytes and resulting in a cutaneous depigmentation. Treatment for vitiligo remains a challenge for dermatologists; thus, it is frustrating both for physicians and patients. The objective of this study was to evaluate a combination treatment characterized by the use of a leukocyte-rich platelet-rich plasma, which is particularly rich in monocytes (defined here as monocyte-rich PRP), in combination with a 1927 nm fraxel laser and a 308 nm excimer laser.

View Article and Find Full Text PDF

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a new pathogen agent causing the coronavirus infectious disease (COVID-19). This novel virus originated the most challenging pandemic in this century, causing economic and social upheaval internationally. The extreme infectiousness and high mortality rates incentivized the development of vaccines to control this pandemic to prevent further morbidity and mortality.

View Article and Find Full Text PDF

Basal cell carcinoma (BCC), the most common type of skin cancer in the world, usually arises in sun-exposed areas of the skin. The therapeutic approach to periocular BCC has changed in the last few years. Currently the treatment, considering the delicate localization of the disease, must not only ensure complete recovery from the neoplastic disease, but must also satisfy functional and aesthetic criteria.

View Article and Find Full Text PDF

Background: Laser technology provides different solutions for scar treatment from the traditional ablative lasers to the more recent fractional devices.

Patients And Methods: We present the case of a young woman treated for scars induced by severe whipping since the age of 10. She received four monthly nonablative fractional 1550 nm erbium glass laser treatments.

View Article and Find Full Text PDF

Objective: We treated two patients with recalcitrant lichen sclerosus (LS) of the penis with a combination of 1927 nm thulium fiber laser and methyl-aminolevulinate (MAL) photodynamic therapy (PDT).

Background Data: Therapy of LS is based on topical potent steroids, emollients, and topical calcineurin inhibitors. Circumcision is effective, but not always accepted.

View Article and Find Full Text PDF